These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
512 related articles for article (PubMed ID: 19570087)
21. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Shazad B; Abbaszadeh B; Khamesipour A Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817 [TBL] [Abstract][Full Text] [Related]
22. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452 [TBL] [Abstract][Full Text] [Related]
23. Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Iraji F; Vali A; Asilian A; Shahtalebi MA; Momeni AZ Dermatology; 2004; 209(1):46-9. PubMed ID: 15237267 [TBL] [Abstract][Full Text] [Related]
24. Intralesional injection of 2% zinc sulfate solution in the treatment of acute old world cutaneous leishmaniasis: a randomized, double-blind, controlled clinical trial. Firooz A; Khatami A; Khamesipour A; Nassiri-Kashani M; Behnia F; Nilforoushzadeh M; Pazoki-Toroudi H; Dowlati Y J Drugs Dermatol; 2005; 4(1):73-9. PubMed ID: 15696988 [TBL] [Abstract][Full Text] [Related]
25. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. Soto J; Valda-Rodriquez L; Toledo J; Vera-Navarro L; Luz M; Monasterios-Torrico H; Vega J; Berman J Am J Trop Med Hyg; 2004 Nov; 71(5):577-81. PubMed ID: 15569787 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran. Mohammadzadeh M; Behnaz F; Golshan Z J Infect Public Health; 2013 Apr; 6(2):120-4. PubMed ID: 23537825 [TBL] [Abstract][Full Text] [Related]
27. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Wortmann G; Miller RS; Oster C; Jackson J; Aronson N Clin Infect Dis; 2002 Aug; 35(3):261-7. PubMed ID: 12115091 [TBL] [Abstract][Full Text] [Related]
28. Antimony in plasma and skin of patients with cutaneous leishmaniasis--relationship with side effects after treatment with meglumine antimoniate. Neves DB; Caldas ED; Sampaio RN Trop Med Int Health; 2009 Dec; 14(12):1515-22. PubMed ID: 19954451 [TBL] [Abstract][Full Text] [Related]
29. [Management of cutaneous leishmaniasis in adults and children]. Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM Med Trop (Mars); 2005 Nov; 65(5):487-95. PubMed ID: 16465821 [TBL] [Abstract][Full Text] [Related]
30. Nodular lymphangitic subcutaneous dissemination after intralesional antimonial treatment for localized cutaneous leishmaniasis. Yébenes M; Cruz I; Cañavate C; Gilaberte M; Baena V; Pujol RM Clin Exp Dermatol; 2008 Mar; 33(2):142-4. PubMed ID: 18076691 [TBL] [Abstract][Full Text] [Related]
31. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study. Esfandiarpour I; Dabiri SH Int J Dermatol; 2007 Aug; 46(8):848-52. PubMed ID: 17651170 [TBL] [Abstract][Full Text] [Related]
32. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Asilian A; Sadeghinia A; Faghihi G; Momeni A Int J Dermatol; 2004 Apr; 43(4):281-3. PubMed ID: 15090013 [TBL] [Abstract][Full Text] [Related]
33. Drug hypersensitivity syndrome induced by meglumine antimoniate. Jeddi F; Caumes E; Thellier M; Jauréguiberry S; Mazier D; Buffet PA Am J Trop Med Hyg; 2009 Jun; 80(6):939-40. PubMed ID: 19478253 [TBL] [Abstract][Full Text] [Related]
34. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice. Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children. Layegh P; Pezeshkpoor F; Soruri AH; Naviafar P; Moghiman T Am J Trop Med Hyg; 2009 Feb; 80(2):172-5. PubMed ID: 19190206 [TBL] [Abstract][Full Text] [Related]
36. Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia. Bermúdez H; Rojas E; Garcia L; Desjeux P; Dujardin JC; Boelaert M; Chappuis F Ann Trop Med Parasitol; 2006 Oct; 100(7):591-600. PubMed ID: 16989685 [TBL] [Abstract][Full Text] [Related]
37. Localized cutaneous leishmaniasis of the plantar region: a 40-year outcome. Diehl ES; Ura S; Fleury RN; de Almeida HL; Barral AM Dermatol Online J; 2008 Dec; 14(12):15. PubMed ID: 19265628 [TBL] [Abstract][Full Text] [Related]
38. Early enlargement of an ulcerated area during leishmaniasis treatment with meglumine antimoniate in Brazil. Romero GA; Molinet FJ; Noronha EF Trans R Soc Trop Med Hyg; 2013 Apr; 107(4):266-8. PubMed ID: 23315614 [TBL] [Abstract][Full Text] [Related]
39. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. Rojas R; Valderrama L; Valderrama M; Varona MX; Ouellette M; Saravia NG J Infect Dis; 2006 May; 193(10):1375-83. PubMed ID: 16619185 [TBL] [Abstract][Full Text] [Related]